ERAS · Erasca, Inc.

This disclosure constitutes a material clinical development milestone for Erasca, as it advances the timeline for the first human data readout of ERAS-0015 — its lead pan-RAS molecular glue candidate. The narrowing to 'no later than mid-May 2026' signals meaningful progress in patient enrollment, dosing, and/or data maturity across both the global AURORAS-1 trial and the China-based JYP0015M101 trial. Unlike routine operational updates, this timing revision directly impacts investor expectations for near-term clinical validation of the company’s core RAS-targeting platform. The dual-trial structure also underscores a de-risked, geographically diversified development strategy: AURORAS-1 tests ERAS-0015 in biomarker-selected RAS-mutant solid tumors broadly, while JYP0015M101 focuses on advanced solid tumors with specific RAS mutations under Joyo’s sponsorship in China — suggesting potential for accelerated regional development and future commercial rights considerations. However, the filing explicitly cautions that actual results may differ due to risks inherent in clinical development, including those detailed in the Form 10-K for the year ended December 31, 2025. As no financial results, agreements, or executive changes are disclosed, the materiality derives entirely from the significance of this imminent clinical inflection point for a high-potential oncology asset.